Results 41 to 50 of about 35,838 (264)

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Journal of Clinical Oncology, 2023
PURPOSE Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2–mutant (
Koichi Goto, Y. Goto, T. Kubo, K. Ninomiya, Sang-We Kim, D. Planchard, M. Ahn, E. Smit, A. D. de Langen, M. Pérol, E. Pons-Tostivint, S. Novello, H. Hayashi, J. Shimizu, Dong-Wan Kim, C. Kuo, Jie Yang, K. Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, P. Jänne   +23 more
semanticscholar   +1 more source

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

Breast Cancer: Targets and Therapy, 2021
Anna S Linehan,1 Orla M Fitzpatrick,1 Patrick G Morris1,2 1Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; 2Department of Medical Oncology, Royal College of Surgeons in Ireland, Dublin, IrelandCorrespondence: Patrick G ...
Linehan AS, Fitzpatrick OM, Morris PG
doaj  

Management of Chemotherapy-Induced Nausea and Vomiting with Trastuzumab Deruxtecan: A Case Series [PDF]

Breast Care, 2020
<b><i>Introduction:</i></b> Trastuzumab deruxtecan is a monoclonal antibody linked to a chemotherapy moiety that was recently approved by the Food and Drug Administration (FDA) for the treatment of metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancers.
Matthew Stankowicz, Kathleen K. Harnden, Lauren Mauro, Angela Pennisi   +3 more
openaire   +3 more sources

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer

Scientific Reports, 2023
Trastuzumab is used to treat HER2-amplified metastatic gastric cancer; however, most patients become trastuzumab-resistant within a year. Knowledge of the mechanisms underlying trastuzumab resistance is required to overcome this limitation.
Juin Park, Sun Kyoung Kang, Woo Sun Kwon, Inhye Jeong, Tae Soo Kim, Seo Young Yu, Sang Woo Cho, Hyun Cheol Chung, Sun Young Rha   +8 more
doaj   +1 more source

Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia

Опухоли женской репродуктивной системы
Background. Reducing malignant mortality to 185 cases per 100,000 by 2030 is one of goals of the state program “Healthcare development” in Russia.Aim. To assess potential impact of using trastuzumab deruxtecan in patients with breast cancer on reducing ...
N. A. Avxentyev, Yu. V. Makarova, A. S. Makarov   +2 more
doaj   +1 more source

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

Journal of Clinical Oncology, 2023
PURPOSE To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS ...
T. Nishikawa, K. Hasegawa, Koji Matsumoto, M. Mori, Y. Hirashima, K. Takehara, K. Ariyoshi, Tomoyasu Kato, S. Yagishita, A. Hamada, M. Kawasaki, S. Kawashima, Sawako Tomatsuri, Y. Nagasaka, H. Yoshida, R. Machida, A. Hirakawa, K. Nakamura, K. Yonemori   +18 more
semanticscholar   +1 more source

Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response. [PDF]

NPJ Breast Cancer
Body composition is an important predictor in cancer patients, with skeletal muscle loss and high adiposity associated with poorer prognosis. This study evaluated how body composition affects treatment efficacy in 48 women with metastatic breast cancer receiving trastuzumab deruxtecan. Using computed tomography, skeletal muscle, visceral adipose tissue
Yaacobi Peretz S, Kessner R, Bar Y, Sonnenblick A, Lerner S, Deutsch-Lukatsky A, Popuri K, Beg MF, Shachar SS.   +8 more
europepmc   +4 more sources

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Nature Network Boston
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (mBC) and stable or active (untreated ...
N. Harbeck, E. Ciruelos, G. Jerusalem, Volkmar Müller, N. Niikura, G. Viale, Rupert Bartsch, C. Kurzeder, Michaela J Higgins, R. M. Connolly, S. Baron-Hay, M. Gion, V. Guarneri, G. Bianchini, H. Wildiers, S. Escrivá-de-Romaní, M. Prahladan, Helen Bridge, Nataliya Kuptsova-Clarkson, N. Scotto, Sunil Verma, N. U. Lin   +21 more
semanticscholar   +1 more source

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)

npj Breast Cancer, 2023
Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 ...
N. Niikura, T. Yamanaka, Hironori Nomura, K. Shiraishi, Hiroki Kusama, Mitsugu Yamamoto, K. Matsuura, K. Inoue, S. Takahara, Shosuke Kita, Miki Yamaguchi, T. Aruga, N. Shibata, A. Shimomura, Y. Ozaki, Shuji Sakai, Yoko Kiga, Tadahiro Izutani, K. Shiosakai, J. Tsurutani   +19 more
semanticscholar   +1 more source

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective

Current Oncology, 2023
Ongoing advances in precision cancer therapy have increased the number of molecularly targeted and immuno-oncology agents for a variety of cancers, many of which have been associated with a risk of pulmonary complications, among the most concerning being drug-induced interstitial lung disease/pneumonitis (DI-ILD).
Jan-Willem Henning, Christine Brezden-Masley, Karen Gelmon, Stephen Chia, Shane Shapera, Micheal McInnis, Daniel Rayson, Jamil Asselah   +7 more
openaire   +3 more sources